article thumbnail

Gepirone

New Drug Approvals

However, in 2012 it once again failed to convince the FDA of its qualities for treating anxiety and depression. [5] 5] In December 2015, the FDA once again gave gepirone a negative review for depression due to concerns of efficacy. [12] 12] However, in March 2016, the FDA reversed its decision and gave gepirone ER a positive review. [13]

FDA
article thumbnail

A Visual Guide to Genome Editors

Codon

The treatment, now known as Casgevy, became the first CRISPR-based therapy to gain FDA approval, in 2023. Therapeutics There are no FDA-approved therapies built upon Cas12, but the enzyme is currently being used in multiple clinical trials.

DNA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Landiolol

New Drug Approvals

Landiolol 133242-30-5 ONO-1101 Ono 1101 WHO 7516 FDA APPROVED 11/22/2024, Rapiblyk , To treat supraventricular tachycardia C25H39N3O8 509.6 FDA Approves AOP Health’s Rapiblyk (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting” (Press release). June 2011). 24 August 2022.

FDA
article thumbnail

PRITELIVIR MESYLATE

New Drug Approvals

7] If the virus also acquires resistance to foscarnet, then there is currently no FDA approved treatment. The use of foscarnet is commonly accompanied by restrictive toxicity, particularly nephrotoxicity. [7] 16] The helicase primase complex is encoded separately from the viral DNA polymerase (encoded by the UL30 gene). . Field, H.J.;

article thumbnail

Educating Patients about Generic Drugs: Strategies for Success

Drug Patent Watch

Explain the FDA Approval Process Many patients are unaware of the rigorous approval process generic drugs must undergo. Educate them about the FDA’s role in ensuring the safety and efficacy of generic medications. .” ” Health Affairs, 2011. ” WHO.int, 2020. Shrank, W.H.,

article thumbnail

FDA Approves Pfizer Med for Rare Form of Pediatric Non-Hodgkin Lymphoma

The Pharma Data

Food and Drug Administration (FDA) approved Pfizer ’s Xalkori (crizotinib) for pediatric patients one year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive. Manuel Esteban/Shutterstock.

article thumbnail

Lupus Foundation of America Sees Big Win with FDA Approval of Benlysta for Lupus Nephritis

The Pharma Data

The FDA first approved Benlysta for lupus in 2011. Up to 60 percent of people with lupus will develop lupus nephritis. Benlysta is a human monoclonal antibody sold by GSK. However, at that time, Benlysta had not been studied for use in individuals with severe lupus nephritis.